Abate Kristin 4
4 · Karyopharm Therapeutics Inc. · Filed Mar 4, 2025
Insider Transaction Report
Form 4
Abate Kristin
Chief Accounting Officer
Transactions
- Award
Common Stock
2025-02-28+933→ 10,284 total - Award
Stock Option (right to buy)
2025-02-28+1,866→ 1,866 totalExercise: $7.95Exp: 2035-02-27→ Common Stock (1,866 underlying)
Footnotes (3)
- [F1]Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended (the "2022 Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2026.
- [F2]Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.
- [F3]This option was granted on February 28, 2025 pursuant to the 2022 Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.